DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Lampert EJ, Zimmer A, Padget M. et al.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Clin Cancer Res 2020;
26: 4268-4279
DOI: 10.1158/1078-0432.CCR-20-0056.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.